Population-wide Observational Study in Brazil: Prophylactic Use of Ivermectin Reduces COVID-19 Mortality, Hospitalization & Infection

Lucy Kerr, a Brazilian physician, participated in an Ivermectin summit hosted by TrialSite. Kerr and four other medical researchers, two affiliated with Brazilian academic medical centers and one from a Cuban biotech institute were involved in the study of the efficacy of the generic, regulatory approved antiparasitic drug in three different municipalities in Brazil covered by TrialSite back in September 2020. Most recently, Dr. Kerr and colleagues posted the results of a citywide prevention program using ivermectin, implemented in Itajai in the south of Brazil. The prospective, observational study analyzed citywide COVID-19 data between July 2020 to December 2020. The study logistics of instructional review board approval and registry data analysis occurred retrospectively due to the urgent pandemic conditions at the time.

TrialSite emphasizes this research hasn’t been peer-reviewed yet and shouldn’t be cited as medical evidence. This media platform focuses on medical research and these results require further verification. The study data derives from a public health program in response to COVID-19 in the municipality of Itajai in Santa Catarina, Brazil. This ci...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee